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PAST
The incidence of cutaneous melanoma has risen faster
than any other malignancy worldwide.1 Despite decades of
research into tumor biology, as well as surgical and med-
ical treatments, melanoma remains one of the most
treatment-resistant cancers.
Biomarkers of disease help to stratify patients for differ-
ent cancer treatments. The neutrophil–lymphocyte ratio
(NLR) represents the host systemic inflammatory response
to cancer and is strongly associated with survival, recur-
rence, metastatic burden, and treatment response.2 A recent
systematic review of NLR in melanoma showed that a
NLR[ 2 was associated with a higher risk of death3;
however, the majority of these data related to patients with
metastatic disease, while the remainder had stage IIIc dis-
ease or very high-risk primaries. As the majority of patients
(approximately 90%) have localizedmelanoma, the external
validity of this biomarker research is weak, which provides
the rationale for our multicenter work.
PRESENT
We observed that a low NLR (\ 2.5) was associated
with over twice the risk of death from melanoma.4 This
finding contrasts with the observed direction of effect in
most other solid organ cancers or advanced (stage III/IV)
melanoma. This observation was compounded after strati-
fying patients by sentinel lymph node status, whereby
patients with nodal metastases and a low NLR (‘poor
immune responders’) had the worst survival. We suggest
that because the NLR is a proxy for the host inflammatory
response, a low NLR may represent a deficient immune
response which might allow localized disease to propagate.
This finding is potentially clinically important because if
we could identify these ‘poor immune responders’ at
baseline, adjuvant immunotherapy could be better utilized.
Although we made substantial efforts to mitigate the
risks of methodological biases in our work, further
prospective work is needed to define the associations
between localized melanoma and hematological
biomarkers.
FUTURE
The use of adjuvant immunotherapy for resected stage
III/IV disease is now commonplace. Trials of neoadjuvant
immunotherapy in high-risk resectable and oligometastatic
melanoma prior to resection are now underway,5 which is
both interesting and concerning because immunotherapy
induces serious adverse events in approximately 15% of
patients receiving ipilimumab monotherapy, 2% receiving
pembrolizumab, and approximately 5% receiving nivolu-
mab. Therefore, we suggest that the selection of patients
for neoadjuvant immunotherapy is of paramount impor-
tance to prevent treatment-related harm. At the time of
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diagnosis, we have shown that hematological biomarkers
might help to identify ‘poor immune responders’ who stand
to gain the most from neoadjuvant immunotherapy.
Ultimately, multivariable modeling of biomarkers (he-
matological, histopathological, genomic, imaging, and
phenotypic, etc.) will improve the selection of patients for
different treatments. To implement this type of ‘personal-
ized cancer treatment’ and improve the management of
melanoma, we must share data derived from international
collaborations and exploit modern computational methods
of modeling big data.
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